Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.

Hair loss discussion includes Fluridil 7% treatment. Users report no side effects and convenient use, considering increasing to 10%.

The user experienced significant hair thinning despite using finasteride and minoxidil, leading to concerns about whether it's a temporary shed or a more serious issue. They plan to start using RU58841 and are advised to consult a doctor to rule out other causes like autoimmune disorders.

The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

A user switched from finasteride to dutasteride and experienced continuous shedding but is now seeing some regrowth. Others shared similar experiences, noting that shedding can continue but hair often improves over time with dutasteride.

A user in the UAE is facing customs issues with ordering Fluridil (Eucapil) and is considering ordering smaller quantities or switching to Pyrilutamide. They are also using finasteride daily to maintain hair and are unsure of Fluridil's effectiveness.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

The user experienced increased hair thinning after switching from finasteride and minoxidil to dutasteride, despite some users suggesting it might be a temporary shedding phase. The user is considering using RU58841 but is unsure about its safety.

A 31-year-old has been using finasteride, dutasteride, and oral minoxidil for hair loss. They noticed a sudden triangular thinning patch on their scalp and are seeking advice, questioning if it could be medication-related.

Dutasteride mesotherapy is discussed as a hair loss treatment, with opinions on its effectiveness compared to oral dutasteride. The treatment is noted for being expensive, potentially painful, and more popular in Europe, with some users questioning its advantages over traditional methods.

The conversation is about hair shedding experienced while using finasteride (fin) for hair loss treatment. Users discuss their experiences with finasteride, minoxidil (min), and other treatments, noting that shedding is often a sign that the treatment is working.

The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.

The conversation discusses GT20029 as a potential cure for hair loss and includes information on specific treatments used. Minoxidil, finasteride, and RU58841 are mentioned as related treatments.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

The post discusses using a topical tincture containing zinc, azelaic acid, and other ingredients to inhibit 5 alpha-reductase activity for treating hair loss. The user plans to try this natural alternative before using finasteride or RU58841.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

Breezula's effectiveness may depend on the vehicle used for its application, with concerns about the grey market version's formulation. Phase 3 results are promising, but skepticism remains about the grey market product's authenticity and effectiveness.

Hair loss discussion includes using fluridil (eucapil), minoxidil, and finasteride. One person takes 1 vial of fluridil daily and 1mg of finasteride every other day for effective treatment with minimal side effects.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Switching from finasteride to dutasteride can lead to increased shedding and hair loss for some, while others see improvement. The effectiveness varies, with some users experiencing better results with dutasteride, while others find finasteride more beneficial.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

A group buy for products to treat hair loss, such as Minoxidil, Finasteride and RU58841. Participants are interested in adding more people before ordering the next order.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.